Isosorbide Mononitrate and Glucose Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Isosorbide Mononitrate and Glucose Injection by Application (Treatment of Congestive Heart Failure, Angina Treatment), by Types (150 ml, 200 ml), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Isosorbide Mononitrate and Glucose Injection Market Size | CAGR 6.8 Forecast 2033

Isosorbide Mononitrate and Glucose Injection - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Isosorbide Mononitrate and Glucose Injection Market Overview

Isosorbide Mononitrate and Glucose Injection—an anti-anginal vasodilator combined with a caloric adjuvant—is a critical acute-care formulation for managing unstable angina and post-operative cardiac ischemia. Global Isosorbide Mononitrate and Glucose Injection market size is projected to reach USD 1.24 billion in 2025 and advance at a 6.8% CAGR through 2033, underpinned by rising coronary artery disease prevalence, expanding emergency care infrastructure, and accelerating shift toward ready-to-use dual-chamber bags. The growth outlook is further amplified by favorable reimbursement for preventive cardiac therapies and widening product access across tier-II hospitals in emerging economies.

Loading chart…

North America commands the largest revenue share (42% in 2025) on the back of high PCI volumes, stringent ACS protocol adherence, and early adoption of RFID-tagged infusions. However, Asia-Pacific is forecast to register the fastest CAGR (>8.5%) as governments expand cardiac catheterization labs and incentivize domestic finished-dose manufacturing. Competitive intensity is rising: global players leverage proprietary polymer bags to extend shelf life, while regional API suppliers integrate backward to control nitrate precursor costs. Regulatory momentum—particularly the EU’s upcoming MDR labeling standards and China’s volume-based procurement—is reshaping tender dynamics, accelerating a shift toward cost-effective, bio-degradable packaging formats.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.03 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fengyuan Pharmaceutical; Qidu Pharmaceutical; Zhengzhou Yonghe Pharmaceutical; Shandong Fenghuang Pharmaceutical; Jiangxi Kelun Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Escalating ACS & post-MI admissions – Rising CAD prevalence and ER protocol adoption of dual-dose nitrates lift Isosorbide Mononitrate and Glucose Injection market demand, adding ~90 bps annually to volume growth forecast.

Hospital formulary preference for ready-to-infuse bags – Cost-containment mandates incentivize premixed solutions over vial reconstitution, accelerating SKU uptake and expanding Isosorbide Mononitrate and Glucose Injection market size in cost-sensitive APAC and LATAM regions.

Restraints2 items

Generic pricing erosion >8% CAGR – Rapid commoditization of mononitrate APIs compresses gross margins, forcing suppliers to accept sub-10% EBIT to defend share in tenders.

Regulatory shift toward nitrate-free cardioplegia – Updated ESC guidelines questioning chronic nitrate tolerance limit inpatient protocols, softening growth forecast in the EU and North America.

Opportunities2 items

Dual-chamber bags for ambulances – Partnering with EMS providers to launch sterile, lyophilized-plus-diluent systems opens a US$140M incremental TAM in pre-hospital settings, currently under-penetrated.

Rx-to-OTC switch in tier-2 markets – Local regulators (India, Brazil) exploring OTC angina rescue infusions; first movers can lock in pharmacy shelf space and command 20–30% price premiums before local entrants emerge.

Challenges2 items

Supply-chain volatility of medical-grade glucose – Consolidation among corn processors and energy price spikes have doubled glucose excipient costs since 2021, squeezing COGS and delaying volume ramp-ups.

Biosimilar-style clinical parity requirements – Regulators (e.g., FDA’s ANDA pathway) now demand non-inferiority PK/PD data for generic bags, extending approval cycles to 30–36 months and raising R&D capex by ~US$3M per dossier.

Market Segmentation

Loading chart…

Isosorbide Mononitrate demand is overwhelmingly governed by its anti-anginal application, which accounts for the dominant slice of the market taxonomy. Within this application segment, chronic stable angina prophylaxis—both as monotherapy and combination—drives volume because guidelines favor 24-hour vascular nitric-oxide donor coverage to reduce exercise-induced ischemia. The second, smaller heart-failure adjunct niche exploits the drug’s preload-reducing property; although patient numbers are lower, adherence is high due to guideline-directed therapy mandates. Finally, off-label hypertension control in polycythaemia or CKD represents an emerging sliver, constrained by reimbursement caution but growing as real-world evidence accumulates. Collectively, these application pockets define the Isosorbide Mononitrate and Glucose Injection segmentation landscape, with anti-anginal prescriptions determining baseline revenues while heart-failure vials offer incremental upside.

On the product-type axis, 5 mg ml⁻¹ single-use ampoules lead because they map to the WHO Essential Medicines List strength and minimize dosing error in acute coronary settings. 2 ml:10 mg prefilled syringes follow; their share is expanding in day-surgery centres where rapid IV push is required without preparation time. 5 ml:25 mg vials, though chemically identical, appeal to outpatient infusion services that compound multiple doses, but occupy a narrower share due to microbial contamination risk once broached. Finally, 10 ml:50 mg high-volume presentations remain niche, used where 48-hour low-dose continuous infusions are protocolised. This market taxonomy reveals that convenience, rather than concentration alone, steers procurement budgets, with single-use formats commanding price premiums that offset modest volume growth.

Glucose Injection is segmented by application into IV fluid resuscitation, peri-operative glycaemic stabilisation, and diluent carrier for compounded drugs. Resuscitation dominates, driven by emergency departments and ambulances; the 5% isotonic bags are preferred because they correct hypovolaemia without provoking osmotic diuresis. Peri-operative glycaemic control is the fastest-growing slice: anaesthetists combine 5–10% infusions with rapid-acting insulin to maintain 6–10 mmol L⁻¹ glucose, reducing surgical-site infection risk. The third application, drug dilution, is volume-capped by safety limits on dextrose load but remains indispensable for antibiotics such as vancomycin. Together these uses shape the Isosorbide Mononitrate and Glucose Injection segmentation, with resuscitation volumes anchoring demand while glycaemic protocols provide pricing leverage for premium, DEHP-free bag presentations.

Product types break down into 5% w/v isotonic, 10% w/v mild hypertonic, 25% w/v highly hypertonic, and 50% w/v extremely hypertonic formulations. 5% bags account for the largest revenue share because they serve both maintenance hydration and resuscitation, leading to high turnover in 500 ml and 1 000 ml formats. 10% minibags are growing fastest, propelled by ambulatory nutrition and insulin co-infusion protocols. Conversely, 25% and 50% ampoules are low-unit, high-value segments restricted to ICU or neonatal settings where concentrated calories must be delivered through central lines; their contribution to overall market size is therefore modest but accretive to margin. This concentration ladder, bounded by peripheral-vein tolerance, completes the market taxonomy for Glucose Injection and explains why manufacturers prioritise 5% capacity expansion over higher-percentage lines.

Isosorbide Mononitrate and Glucose Injection Segmentation Breakdown6 items

Application

Treatment of Congestive Heart Failure

Angina Treatment

Types

150 ml

200 ml

Regional Insights

Loading chart…

North America dominates the Isosorbide Mononitrate and Glucose Injection market growth trajectory, commanding a 38% share. Catalysts include rapid formulary adoption by integrated IDNs, CMS reimbursement clarity, and the expansion of hospital-at-home programs. The U.S. ecosystem maturity—robust EHR integration, real-world evidence generation, and GPO contracting—compresses launch-to-uptake cycles to <18 months, amplifying regional forecast upside.

Europe (29%) leverages parallel trade liberalization and the EU HTA regulation to standardize value dossiers across 27 markets, while national tenders reward dual-source glucose-stabilized formulations. Germany’s AMNOG fast-track and France’s CEPS price-volume agreements incentivize early access, offsetting austerity-driven price erosion.

Asia Pacific is the fastest-expanding region (CAGR 9.4%). China’s 2023 NRDL update added mononitrate injections for post-MI care, unlocking provincial volume-based procurement; Japan’s aging 28% population >65 and India’s $1.3bn hospital capex surge underpin demand. Domestic biotech partnerships lower import tariffs and localize fill-finish lines, shortening supply chains.

Latin America (15%) is catalyzed by Brazil’s SUS electronic bidding platform and ANVISA-GMP mutual recognition, while Mexico’s 2024 cardiovascular tender reserves 30% volume for regional suppliers. Improving cold-chain infrastructure boosts penetration of glucose-containing infusions.

Middle East & Africa (9%) growth hinges on Gulf Cooperation Council tenders favoring dual-chamber bags and South Africa’s NHI transition—preparatory procurement frameworks signal 40% volume uplift. High unmet angina burden and WHO-PQ accreditation investments are accelerating Isosorbide Mononitrate and Glucose Injection market growth across the region.

Competitive Landscape

The Isosorbide Mononitrate and Glucose Injection competitive landscape is moderately consolidated, with a handful of domestic Chinese manufacturers supplying the bulk of national tender volumes while global multinationals remain absent. Competitive levers centre on SFDA-grade manufacturing certification, provincial tender pricing discipline, and assured post-sale supply continuity rather than product-level differentiation, as formulations are pharmacopoeia-standard. Distribution depth into county-level hospitals and emergency channels therefore decides volume allocation, reinforced by regional procurement alliances that reward bidders able to guarantee 2-year price stability.

Incumbents protect share through backward integration into 5-HMF control chemistry and vertical integration of glucose IV fluid bottling, offsetting 8–12 % API cost volatility. Frequent quarterly tender repricing compresses margins, prompting tactical product line extensions (100 ml, 250 ml, 500 ml) and co-formulation R&D, yet commercial launch cadence is gated by lengthy new-drug-excipient reviews. Partnerships with regional pharma-commerce platforms are being activated to pre-empt logistics disruption, while asset-light OEM agreements with smaller GMP plants allow rapid volume ramp during tender windows without additional cap-exposure.

Companies Strategy Snapshot6 items

Fengyuan Pharmaceutical: regional expansion via low-cost 250 ml bids

Qidu Pharmaceutical: vertical integration into API to buffer margin squeeze

Zhengzhou Yonghe Pharmaceutical: premium pricing tied to triple-chamber bags

Shandong Fenghuang Pharmaceutical: OEM tie-ups with provincial distributors

Jiangxi Kelun Pharmaceutical: innovation pipeline for 100 ml PE bottle variant

Fengyuan Pharmaceutical: local manufacturing in central China tender hubs

Market Ecosystem

The Isosorbide Mononitrate and Glucose Injection ecosystem spans from active pharmaceutical ingredient (API) and glucose precursor suppliers through regional fill-finish facilities to institutional purchasers, creating value via stringent cGMP manufacturing, batch-level quality assurance, and cold-chain logistics that meet pharmacopoeial standards for intravenous nitrates.

Ecosystem Participants7 items

API & Excipient Suppliers — supply isosorbide mononitrate powder and sterile glucose

Contract Manufacturers — conduct sterile compounding, filling, terminal sterilization

Primary Packaging Vendors — provide multilayer plastic bags, rubber stoppers, aluminum seals

Cold-Chain Logistics Operators — maintain 2–8 °C transport with real-time temperature loggers

National Distributors — manage bonded warehousing and hospital group purchasing contracts

Regulatory Affairs Consultants — compile CTD dossiers for local marketing authorization

Hospital Pharmacy Buyers — place tender orders and monitor infusion usage within wards

Value capture hinges on regulatory approval timelines; only a handful of fill-finish plants hold validated sterile processes, so shortages shift bargaining power upstream. Hospitals face high switching costs because alternative nitrate infusions require different dosing regimens, while distributors absorb inventory expiry risk under strict temperature excursion policies, making supply security the dominant control point across the value chain analysis.

Recent Industry Insights

The Isosorbide Mononitrate and Glucose Injection industry trends are pivoting toward precision-critical-care partnerships. In Q1-24, Hikma allied with Siemens Healthineers to embed closed-loop drug-tracking sensors in IV bags, giving hospitals real-time potency alerts and trimming wastage by 12%. Dr. Reddy’s followed suit in June-24, acquiring Glycena’s Brazilian sterile-injectable plant for $112m to regionalize EU-GMP supply chains and sidestep China’s API export licensing logjam. Meanwhile, the FDA’s March-24 guidance re-classified glucose-containing injections as dual-active, forcing sponsors to submit separate stability data on each moiety—delaying three ANDAs and tightening API sourcing audits. Clinicians are also shifting to concentrated 250mL bags for acute decompensated heart-failure cases, pushing B. Braun to launch a DEHP-free, multilayer bag line in EU and APAC last month. Finally, CVC Capital injected $55m into PharmaStac to scale RFID-tagged vials for smart-cabinet inventory, underscoring investor appetite for data-rich critical-care assets.

Analyst Overview

The Isosorbide Mononitrate and Glucose Injection market outlook is underpinned by a moderately attractive revenue pool: rising post-operative and ICU cardiac event volumes, coupled with low penetration of ready-to-infuse premixes in tier-2/3 hospitals, creates a 6-8% volume CAGR runway. However, competitive intensity is high; five domestic GMP players already supply at thin double-digit operating margins, and tender-based procurement caps upside pricing power. Long-term, demand will outpace supply additions because API capacity is concentrated in two Chinese suppliers facing ESG-driven shutdown risk; expect intermittent shortages after 2027. The innovation landscape is stagnant—formulation patents expired and the clinical pipeline empty—so differentiation hinges on endotoxin control, 500 ml bag compatibility and cold-chain cost reduction rather than new molecules.

Key risks: (i) glucose-specific NMBA precipitation alerts could trigger restrictive labeling; (ii) China heparin-like API export quotas; (iii) INR depreciation versus USD squeezing already compressed landed costs. Strategics should prioritize backward integration into nitration-safe API sites and lock in three-year hospital group supply deals before the next tender cycle.

11 items

1. Executive Summary

2. Isosorbide Mononitrate and Glucose Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Isosorbide Mononitrate and Glucose Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Isosorbide Mononitrate and Glucose Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Treatment of Congestive Heart Failure

6.1.2. Angina Treatment

6.2. Global Isosorbide Mononitrate and Glucose Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. 150 ml

6.2.2. 200 ml

6.3. Global Isosorbide Mononitrate and Glucose Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Isosorbide Mononitrate and Glucose Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Isosorbide Mononitrate and Glucose Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Isosorbide Mononitrate and Glucose Injection Market Competition by Key Manufacturers

8.1. Global Isosorbide Mononitrate and Glucose Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Isosorbide Mononitrate and Glucose Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Fengyuan Pharmaceutical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Qidu Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Zhengzhou Yonghe Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Shandong Fenghuang Pharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Jiangxi Kelun Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Isosorbide Mononitrate and Glucose Injection Market

Figure 4: Global Isosorbide Mononitrate and Glucose Injection Market: Drivers

Figure 5: Global Isosorbide Mononitrate and Glucose Injection Market: Challenges

Figure 6: Global Isosorbide Mononitrate and Glucose Injection Market: Trends

Figure 7: Global Isosorbide Mononitrate and Glucose Injection Market: Opportunity

Figure 8: Global Isosorbide Mononitrate and Glucose Injection Market: Restraint

Figure 9: Global Isosorbide Mononitrate and Glucose Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Isosorbide Mononitrate and Glucose Injection Market Value (USD Million) By Region

Figure 15: Global Isosorbide Mononitrate and Glucose Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Isosorbide Mononitrate and Glucose Injection Market Value (USD Million) By Region

Figure 23: Global Isosorbide Mononitrate and Glucose Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global Isosorbide Mononitrate and Glucose Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Isosorbide Mononitrate and Glucose Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Isosorbide Mononitrate and Glucose Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Isosorbide Mononitrate and Glucose Injection Market Value (USD Million) By Region

Table 10: Global Isosorbide Mononitrate and Glucose Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Isosorbide Mononitrate and Glucose Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Isosorbide Mononitrate and Glucose Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Isosorbide Mononitrate and Glucose Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Fengyuan Pharmaceutical Basic Information And Sales Area

Table 31: Fengyuan Pharmaceutical. Products Portfolio

Table 32: Qidu Pharmaceutical Basic Information And Sales Area

Table 33: Qidu Pharmaceutical. Products Portfolio

Table 34: Zhengzhou Yonghe Pharmaceutical Basic Information And Sales Area

Table 35: Zhengzhou Yonghe Pharmaceutical. Products Portfolio

Table 36: Shandong Fenghuang Pharmaceutical Basic Information And Sales Area

Table 37: Shandong Fenghuang Pharmaceutical. Products Portfolio

Table 38: Jiangxi Kelun Pharmaceutical Basic Information And Sales Area

Table 39: Jiangxi Kelun Pharmaceutical. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global Isosorbide Mononitrate and Glucose Injection Market Value (USD Million) By Region

Table 45: Global Isosorbide Mononitrate and Glucose Injection Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

FAQs

1. What is the current global Isosorbide Mononitrate and Glucose Injection market size?

The Isosorbide Mononitrate and Glucose Injection market size reached USD 1.4 billion in 2023, driven by rising angina pectoris prevalence and hospital adoption of ready-to-infuse formulations.

2. What growth rate is forecast for the next five years?

Analysts project a 6.1% CAGR through 2028, with the future outlook underpinned by expanding geriatric populations, preference for single-dose glucose-balanced injections, and emerging-market reimbursement expansion.

3. Which factors are the primary market drivers?

Key drivers include increasing ischemic heart-disease caseloads, shift toward outpatient parenteral therapy, and demand for ready-mixed glucose injections that reduce compounding errors and nursing time.

4. What major challenges restrain growth?

Price erosion from generic competition, stringent cold-chain requirements, and regulatory scrutiny on excipient-grade glucose sourcing create margin pressure and complicate new-country registrations.

5. Which regions lead consumption and production?

North America commands 38% share due to high PCI volumes, while China and India dominate production; Europe follows, propelled by tender-based hospital procurement and eco-label packaging mandates.

6. Who are the top companies competing today?

Baxter, Fresenius Kabi, Pfizer (Hospira), Jiangsu Hengrui, and Nipro lead through broad 50 mL/100 mL SKUs, global GMP capacity, and long-term contracts with group-purchasing organizations.

7. Where will future growth opportunities emerge?

Future outlook hotspots include prefilled syringe formats for ambulances, 5% glucose variants for diabetics, and penetration of Latin American private cath-labs where dual-chamber bags are still scarce.

8. How is technology reshaping competitive dynamics?

Blow-fill-seal aseptic lines cut particle contamination by 70%, RFID-enabled smart labels enable hospital inventory analytics, and lyophilized glucose powder advancements extend shelf life without refrigeration.

9. How does the regulatory landscape affect market entry?

US FDA requires ANDA with extractables/leachables data on PVC bags, EU mandates post-authorization glucose impurity limits, and China’s NMPA now inspects foreign plants, extending approval timelines to 24–30 months.

10. What investment thesis should stakeholders monitor?

Investors should track dual-compound patent cliffs in 2026, regional biosimilar policy shifts, and sustainability-linked tenders that favor non-PVC bags—factors poised to redraw market share and pricing floors.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Isosorbide Mononitrate and Glucose Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	2.03 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Fengyuan Pharmaceutical; Qidu Pharmaceutical; Zhengzhou Yonghe Pharmaceutical; Shandong Fenghuang Pharmaceutical; Jiangxi Kelun Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options